Carfilzomib Patent Expiration
Carfilzomib is Used for treating relapsed or refractory multiple myeloma in patients who have received one to three lines of therapy. It was first introduced by Onyx Pharmaceuticals Inc A Wholly Owned Sub Of Amgen Inc
Carfilzomib Patents
Given below is the list of patents protecting Carfilzomib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Kyprolis |
US9493582 (Pediatric) | Alkylated cyclodextrin compositions and processes for preparing and using the same | Aug 27, 2033 | Onyx Pharms Amgen |
| Kyprolis | US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same | Feb 27, 2033 | Onyx Pharms Amgen |
| Kyprolis |
USRE47954 (Pediatric) | Combination therapy with peptide epoxyketones | Apr 21, 2030 | Onyx Pharms Amgen |
| Kyprolis | US9511109 | Combination therapy with peptide epoxyketones | Oct 21, 2029 | Onyx Pharms Amgen |
| Kyprolis | USRE47954 | Combination therapy with peptide epoxyketones | Oct 21, 2029 | Onyx Pharms Amgen |
| Kyprolis |
US7737112 (Pediatric) | Composition for enzyme inhibition | Jun 07, 2028 | Onyx Pharms Amgen |
| Kyprolis | US7737112 | Composition for enzyme inhibition | Dec 07, 2027 | Onyx Pharms Amgen |
| Kyprolis |
US7417042 (Pediatric) | Compounds for enzyme inhibition | Jan 20, 2027 | Onyx Pharms Amgen |
| Kyprolis | US7417042 | Compounds for enzyme inhibition | Jul 20, 2026 | Onyx Pharms Amgen |
| Kyprolis | US7232818 | Compounds for enzyme inhibition |
Apr 14, 2025
(Expired) | Onyx Pharms Amgen |
| Kyprolis | US7491704 | Compounds for enzyme inhibition |
Apr 14, 2025
(Expired) | Onyx Pharms Amgen |
| Kyprolis | US8129346 | Compounds for enzyme inhibition |
Apr 14, 2025
(Expired) | Onyx Pharms Amgen |
| Kyprolis | US8207125 | Compounds for enzyme inhibition |
Apr 14, 2025
(Expired) | Onyx Pharms Amgen |
| Kyprolis | US8207126 | Compounds for enzyme inhibition |
Apr 14, 2025
(Expired) | Onyx Pharms Amgen |
| Kyprolis | US8207127 | Compounds for enzyme inhibition |
Apr 14, 2025
(Expired) | Onyx Pharms Amgen |
| Kyprolis | US8207297 | Compounds for enzyme inhibition |
Apr 14, 2025
(Expired) | Onyx Pharms Amgen |
Carfilzomib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List